AIM IMMUNOTECH INC. (AIM) Spending and interest coverage
- R&D / revenue · 12 months: Value 2885.26%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value -9.52×; Formula and calculation Operating income ÷ reported interest expense..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 2885.26% | Research and development expense / revenue. Period ending 2026-06-30. $2.74M ÷ $95.00K × 100 ≈ 2885.26% |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | -9.52× | Operating income ÷ reported interest expense. $-11.14M ÷ $1.17M ≈ -9.52× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 2.74M USD | Research and Development Expense |
| Revenue | 95.00K USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | (m) | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -11.14M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | 1.17M USD | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: Reported. Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.74M | $95.00K | (m) | $-11.14M | $1.17M | 2885.26% | (m) | -9.52× | Reported |
| 2026-03-31 | $3.33M | $94.00K | (m) | $-10.27M | $992.00K | 3538.30% | (m) | -10.35× | Reported |
| 2025-12-31 | $3.92M | $88.00K | $60.00K | $-11.66M | $812.00K | 4459.09% | 68.18% | -14.36× | Reported |
| 2025-09-30 | $4.53M | $112.00K | $256.00K | $-14.57M | $553.00K | 4040.18% | 228.57% | -26.34× | Reported |
| 2025-06-30 | $5.36M | $121.00K | $586.00K | $-16.61M | $607.00K | 4425.62% | 484.30% | -27.36× | Reported |
| 2025-03-31 | $5.33M | $146.00K | $666.00K | $-17.66M | $637.00K | 3647.95% | 456.16% | -27.72× | Reported |
| 2024-12-31 | $6.20M | $170.00K | $686.00K | $-19.77M | $585.00K | 3645.29% | 403.53% | -33.80× | Reported |
| 2024-09-30 | $7.73M | $190.00K | $551.00K | $-27.92M | (m) | 4070.00% | 290.00% | (m) | (m) |
| 2024-06-30 | $9.03M | $201.00K | $271.00K | $-31.59M | (m) | 4492.54% | 134.83% | (m) | (m) |
| 2024-03-31 | $10.84M | $193.00K | $241.00K | $-33.35M | (m) | 5615.54% | 124.87% | (m) | (m) |
| 2023-12-31 | $10.94M | $202.00K | $243.00K | $-31.92M | (m) | 5415.35% | 120.30% | (m) | (m) |
| 2023-09-30 | $9.85M | $193.00K | $344.00K | $-23.47M | (m) | 5101.55% | 178.24% | (m) | (m) |
| 2023-06-30 | $8.48M | $168.00K | $569.00K | $-21.83M | (m) | 5050.00% | 338.69% | (m) | (m) |
| 2023-03-31 | $8.01M | $157.00K | $794.00K | $-21.07M | (m) | 5099.36% | 505.73% | (m) | (m) |
| 2022-12-31 | $6.99M | $141.00K | $954.00K | $-19.92M | (m) | 4957.45% | 676.60% | (m) | (m) |
| 2022-09-30 | $7.81M | $135.00K | $1.04M | $-21.81M | (m) | 5782.22% | 770.37% | (m) | (m) |
| 2022-06-30 | $8.44M | $147.00K | $1.08M | $-19.22M | (m) | 5742.18% | 734.01% | (m) | (m) |
| 2022-03-31 | $7.28M | $140.00K | $1.28M | $-18.25M | (m) | 5202.86% | 917.14% | (m) | (m) |
| 2021-12-31 | $7.67M | $135.00K | $1.57M | $-18.84M | $67.00K | 5682.96% | 1161.48% | -281.16× | Reported |
| 2021-09-30 | $7.02M | $127.00K | $1.76M | $-16.54M | $122.00K | 5530.71% | 1385.83% | -135.60× | Reported |
| 2021-06-30 | $6.12M | $130.00K | $1.70M | $-15.97M | $168.00K | 4706.92% | 1304.62% | -95.04× | Reported |
| 2021-03-31 | $6.25M | $146.00K | $1.37M | $-15.57M | $400.00K | 4278.08% | 935.62% | -38.93× | Reported |
| 2020-12-31 | $5.72M | $163.00K | $1.04M | $-15.15M | $672.00K | 3509.20% | 635.58% | -22.55× | Reported |
| 2020-09-30 | $4.88M | $171.00K | $800.00K | $-13.09M | (m) | 2854.97% | 467.84% | (m) | (m) |
| 2020-06-30 | $4.97M | $196.00K | $773.00K | $-12.94M | (m) | 2535.71% | 394.39% | (m) | (m) |
| 2020-03-31 | $4.62M | $185.00K | $874.00K | $-12.84M | (m) | 2497.84% | 472.43% | (m) | (m) |
| 2019-12-31 | $4.65M | $140.00K | $853.00K | $-12.44M | (m) | 3322.14% | 609.29% | (m) | (m) |
| 2019-09-30 | $4.20M | $330.00K | $827.00K | $-12.02M | $-4.00M | 1273.03% | 250.61% | (m) | Reported |
| 2019-06-30 | $4.61M | $307.00K | $743.00K | $-11.85M | $251.22K | 1500.33% | 242.02% | -47.17× | Reported |
| 2019-03-31 | $4.85M | (m) | $818.00K | $-11.85M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $4.78M | $367.00K | $929.00K | $-11.50M | $201.00K | 1301.91% | 253.13% | -57.19× | Reported |
| 2018-09-30 | $4.61M | $177.00K | $551.00K | $-11.63M | (m) | 2601.69% | 311.30% | (m) | (m) |
| 2018-06-30 | $3.80M | $229.00K | (m) | $-11.24M | (m) | 1658.08% | (m) | (m) | (m) |
| 2018-03-31 | $3.56M | $409.00K | (m) | $-10.74M | (m) | 870.90% | (m) | (m) | (m) |
| 2017-12-31 | $4.10M | $437.00K | $86.00K | $-11.42M | (m) | 937.76% | 19.68% | (m) | (m) |
| 2017-09-30 | $5.15M | $403.00K | (m) | $-12.71M | (m) | 1277.17% | (m) | (m) | (m) |
| 2017-06-30 | $5.70M | $335.00K | (m) | $-13.28M | (m) | 1702.09% | (m) | (m) | (m) |
| 2017-03-31 | $5.50M | $137.00K | (m) | $-13.37M | (m) | 4011.68% | (m) | (m) | (m) |
| 2016-12-31 | $5.11M | $92.00K | $52.00K | $-13.80M | (m) | 5551.09% | 56.52% | (m) | (m) |
| 2016-09-30 | $4.20M | $103.00K | (m) | $-12.56M | (m) | 4078.64% | (m) | (m) | (m) |
| 2016-06-30 | $4.83M | $104.00K | (m) | $-13.32M | (m) | 4641.35% | (m) | (m) | (m) |
| 2016-03-31 | $6.37M | $136.00K | (m) | $-15.41M | (m) | 4680.88% | (m) | (m) | (m) |
| 2015-12-31 | $8.04M | $133.00K | $121.00K | $-16.65M | $3.00K | 6043.61% | 90.98% | -5550.00× | Reported |
| 2015-09-30 | $9.52M | $146.00K | (m) | $-18.38M | (m) | 6519.86% | (m) | (m) | (m) |
| 2015-06-30 | $9.45M | $168.00K | (m) | $-18.73M | (m) | 5622.02% | (m) | (m) | (m) |
| 2015-03-31 | $9.34M | $157.00K | (m) | $-18.91M | (m) | 5946.50% | (m) | (m) | (m) |
| 2014-12-31 | $8.99M | $197.00K | (m) | $-19.10M | $11.00K | 4562.44% | (m) | -1736.27× | Reported |
| 2014-09-30 | $8.08M | $193.00K | (m) | $-17.94M | (m) | 4188.08% | (m) | (m) | (m) |
| 2014-06-30 | $8.36M | $184.00K | (m) | $-18.07M | (m) | 4544.57% | (m) | (m) | (m) |
| 2014-03-31 | $8.35M | $184.00K | (m) | $-17.72M | $-33.00K | 4538.04% | (m) | (m) | Reported |
| 2013-12-31 | $8.36M | $150.00K | (m) | $-17.17M | $16.00K | 5573.33% | (m) | -1072.94× | Reported |
| 2013-09-30 | $10.58M | $167.00K | (m) | $-21.75M | $-52.00K | 6333.53% | (m) | (m) | Reported |
| 2013-06-30 | $10.76M | $170.00K | (m) | $-22.26M | $-41.00K | 6330.00% | (m) | (m) | Reported |
| 2013-03-31 | $10.18M | $183.00K | (m) | $-21.16M | $62.00K | 5562.30% | (m) | -341.21× | Reported |
| 2012-12-31 | $9.51M | $213.00K | (m) | $-20.34M | $24.00K | 4463.85% | (m) | -847.50× | Reported |
| 2012-09-30 | $7.47M | $198.00K | (m) | $-16.25M | $88.00K | 3770.71% | (m) | -184.60× | Reported |
| 2012-06-30 | $6.86M | $204.00K | (m) | $-14.84M | $41.00K | 3362.25% | (m) | -361.88× | Reported |
| 2012-03-31 | $6.75M | $191.00K | (m) | $-14.45M | $46.00K | 3532.46% | (m) | -314.17× | Reported |
| 2011-12-31 | $6.72M | $161.00K | (m) | $-14.29M | $41.00K | 4175.16% | (m) | -348.66× | Reported |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $7.61M | $135.00K | (m) | $-16.39M | $11.00K | 5639.26% | (m) | -1489.73× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $7.00M | $111.00K | (m) | $-13.26M | $0.00 | 6301.80% | (m) | (m) | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Silexion Therapeutics Corp (SLXN) | $0.001B |